Hubei Biocause Pharmaceutical Co., Ltd. (000627.SZ)

2.3900 -0.0400 (-1.65%) As of 09:50AM CST. Market open.

Hubei Biocause Pharmaceutical Co., Ltd.

122-132 Yangwan Road
Jingmen 448000
China
86 27 6565 1730
https://www.biocause.com

Sector(s): Financial Services
Industry: Insurance - Life
Full-time employees: 1,765

Key executives

Name	Title	Pay	Exercised	Year born
Ms. Wenxia Zhou	Vice Chairman & GM	N/A	N/A	1972
Mr. Dali Chen	CFO & Director	N/A	N/A	1962
Mr. Fei Long	Secretary of the Board & Non-Independent Director	N/A	N/A	1979

Amounts are as of , and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in CNY.

Description

Hubei Biocause Pharmaceutical Co., Ltd. primarily provides life and motor insurance products in China. It also engages in the pharmaceutical, chemical, and new energy fuel businesses. In addition, the company is involved in the contract research and production of APIs, intermediates, and formulations, including tablets, granules, capsules, etc.; and provision of chemicals comprising dimethyl ether gas and a-chloropropionyl chloride. It exports its products to approximately 85 countries, including the United States, the European Union, and internationally. The company is based in Jingmen, China.

Corporate governance

Hubei Biocause Pharmaceutical Co., Ltd.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.